Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
复制标题
DOI：
10.1086/315334
复制
发表时间：
2000-03-01
影响因子：
6.4
通讯作者：
Grant, RM
中科院分区：
文献类型：
--
作者：
Deeks, SG;Barbour, JD;Grant, RM
在380名接受长期蛋白酶抑制剂治疗的HIV感染成人中，检测了血浆HIV RNA水平与外周血CD 4（+）T细胞计数之间的关系。经历病毒学失败（持续HIV RNA >500 copies RNA/mL）的患者的CD 4（+）T细胞计数通常高于治疗前的基线水平，至少随访96周。CD 4（+）T细胞应答与低于治疗前基线的病毒抑制程度直接且独立相关。对于病毒学失败后12周测量的任何给定的HIV RNA水平，接受基于蛋白酶的方案的患者随后的CD 4（+）T细胞下降比未治疗患者的历史对照组慢。这些观察结果表明，血浆HIV RNA水平的短暂或部分下降可对CD 4（+）T细胞水平产生持续影响。
The relationship between plasma human immunodeficiency virus (HIV) RNA levels and peripheral CD4(+) T cell counts was examined in 380 HIV-infected adults receiving long-term protease inhibitor therapy. Patients experiencing virologic failure (persistent HIV RNA >500 copies RNA/mL) generally had CD4(+) T cell counts that remained greater than pretherapy baseline levels, at least through 96 weeks of follow-up. The CD4(+) T cell response was directly and independently related to degree of viral suppression below the pretreatment baseline. For any given HIV RNA level measured 12 weeks after virologic failure, subsequent CD4(+) T cell decline was slower in patients receiving a protease inhibitor-based regimen than in a historical control group of untreated patients. These observations suggest that transient or partial declines in plasma HIV RNA levels can have sustained effects on CD4(+) T cell levels.